^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GUCY2C-targeted CAR-T immunotherapy

    Related drugs:
    Apply
    Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    11/15/2023
    Initiation :
    03/10/2023
    Primary completion :
    03/10/2026
    Completion :
    03/10/2033
    MSLN
    |
    MSLN expression • MSLN positive
    |
    Mesothelin/GPC3/GUCY2C-CAR-T
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms (NCT05287165)
    Phase 1
    Beijing Immunochina Medical Science & Technolog...
    Recruiting
    Last update posted :
    03/18/2022
    Initiation :
    03/10/2022
    Primary completion :
    04/30/2024
    Completion :
    06/30/2024
    GUCY2C
    |
    IM96 CAR-T cells